Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Antibody-drug conjugate (CD30/MMAE)
Brentuximab vedotin
Adcetris · BV
A CD30/MMAE conjugate whose main renal risk is tumor lysis in bulky lymphoma — direct nephrotoxicity is minimal.
MildAntibody-drug conjugate · approved 2011
Hodgkin lymphomaAnaplastic large-cell lymphomaCD30+ T-cell lymphomas
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is minimal. Tumor lysis syndrome occurs at low rates (<=5% in anaplastic large-cell lymphoma experience) and is the principal pathway to AKI/electrolyte disturbance; renal-specific incidence is not quantified.
Source: Howard et al., Ann Hematol 2016 (systematic review)
Mechanism of kidney injury
Kidney injury is largely indirect: rapid lysis of bulky CD30+ tumor causes tumor lysis with urate/phosphate crystal nephropathy and electrolyte shifts. Peripheral neuropathy and cytopenias dominate the direct toxicity profile; clinically meaningful MMAE-driven tubular nephrotoxicity is not a recognized signal at approved doses.
Clinical presentation
With tumor lysis: hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia and rising creatinine, typically early in treatment of bulky/proliferative disease.
Onset
Early — tumor lysis in the first cycle(s) of bulky disease.
Reversibility
Reversible
Anticancer mechanism
Antibody-drug conjugate targeting CD30 and delivering MMAE via a protease-cleavable linker, causing microtubule disruption and apoptosis in CD30+ tumor cells. Approved for Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and other CD30-expressing lymphomas.
Management
Tumor-lysis management (hydration, urate-lowering therapy, electrolyte correction); supportive AKI care.
Risk factors
- High/bulky tumor burden
- Rapidly proliferative lymphoma
- Volume depletion
- Pre-existing CKD
Prevention
- Tumor lysis prophylaxis (hydration, allopurinol/rasburicase) in high-risk patients
- Monitor electrolytes and renal function during initial cycles
Note · Renal risk is mediated by tumor lysis rather than direct tubular toxicity; caution with dosing in severe renal impairment.
Clinical depth
Renal dose adjustment
Per label, severe renal impairment (CrCl <30) increases MMAE exposure and adverse events - use with caution and avoid where alternatives exist; no adjustment needed for mild-moderate impairment. MMAE is a CYP3A4 substrate.
Dialyzability & ESKD dosing
Not appreciably dialyzed (large ADC; protein-bound MMAE). No supplemental dosing guidance for HD/PD.
Differential diagnosis
Tumor lysis AKI (electrolyte signature, early, bulky disease) versus prerenal AKI from intercurrent GI illness. Intrinsic tubular toxicity from MMAE is not an expected diagnosis.
Monitoring
- Tumor lysis labs (K, phosphate, uric acid, calcium, creatinine) during early cycles of bulky disease
- Neurologic exam for peripheral neuropathy and CBC (dominant direct toxicities)
Key trials & series
- Howard Ann Hematol 2016 systematic review (TLS <=5% in ALCL)
- ECHELON-1/ECHELON-2 registrational program (safety backbone)
Clinical pearls
- The kidney risk is the tumor, not the drug: prophylax tumor lysis in bulky CD30+ disease.
- Caution at CrCl <30 - MMAE exposure rises and toxicity increases even though the renal lesion itself is not tubular.
- Neuropathy and neutropenia are the toxicities that actually change management.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of antibody-drug conjugate (cd30/mmae)s.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression (payload-dependent)
Ophthalmic
Keratopathy, uveitis, retinopathy
- Keratopathy (belantamab, mirvetuximab, tisotumab)
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (deruxtecan ADCs)
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Peripheral neuropathy (MMAE payloads)
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269Reports TLS incidence <=5% with brentuximab vedotin in anaplastic large-cell lymphoma.PMIDBrentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.Newland AM et al. · Pharmacotherapy 2013 · PMID 23307550Review of mechanism and toxicity profile (neuropathy, cytopenias), including increased MMAE exposure in renal impairment.PMIDAntibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.Markides DM et al. · Ann Emerg Med 2024 · PMID 39641680Class review of ADC toxicities and acute presentations.PMIDAnticancer Drug-Induced Acute Kidney Injury.Izzedine H et al. · Kidney Int Rep 2017 · PMID 29318217Onconephrology reference for tumor-lysis and hemodynamic AKI mechanisms.
Related agents
Other agents sharing the same signature kidney injury.